Safety and tolerability of a multilineage-differentiating stress-enduring cell-based product in neonatal hypoxic-ischaemic encephalopathy with therapeutic hypothermia (SHIELD trial): a clinical trial protocol open-label, non-randomised, dose-escalation trial

INTRODUCTION: Neonatal hypoxic-ischaemic encephalopathy (HIE) is an important illness associated with death or cerebral palsy. This study aims to assess the safety and tolerability of the allogenic human multilineage-differentiating stress-enduring cell (Muse cell)-based product (CL2020) cells in ne...

Descripción completa

Detalles Bibliográficos
Autores principales: Matsuyama, Nao, Shimizu, Shinobu, Ueda, Kazuto, Suzuki, Toshihiko, Suzuki, Sakiko, Miura, Ryosuke, Katayama, Akemi, Ando, Masahiko, Mizuno, Masaaki, Hirakawa, Akihiro, Hayakawa, Masahiro, Sato, Yoshiaki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Paediatrics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9045108/
https://www.ncbi.nlm.nih.gov/pubmed/35473726
http://dx.doi.org/10.1136/bmjopen-2021-057073

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9045108/
https://www.ncbi.nlm.nih.gov/pubmed/35473726
http://dx.doi.org/10.1136/bmjopen-2021-057073

Ejemplares similares